Severity Assessment in CDKL5 Deficiency Disorder

Scott Demarest\textsuperscript{1,2}, Elia M. Pestana-Knight\textsuperscript{3,4}, Heather E. Olson\textsuperscript{5}, Jenny Downs\textsuperscript{6,7}, Eric D. Marsh\textsuperscript{8}, Walter E. Kaufmann\textsuperscript{9}, Carol-Anne Partridge\textsuperscript{10}, Helen Leonard\textsuperscript{7}, Femida Gwadry-Sridhar\textsuperscript{11}, Katheryn Elibri Frame\textsuperscript{12}, J. Helen Cross\textsuperscript{13}, Richard F. M. Chin\textsuperscript{14}, Sumit Parikh\textsuperscript{4}, Axel Panzer\textsuperscript{15}, Judith Weisenberg\textsuperscript{16}, Karen Utley\textsuperscript{17}, Amanda Jaksha\textsuperscript{17}, Sam Amin\textsuperscript{18}, Omar Khwaja\textsuperscript{19}, Orrin Devinsky\textsuperscript{20}, Jeffery L. Neu\textsuperscript{21}, Alan K. Percy\textsuperscript{22}, and *Tim A. Benke\textsuperscript{1,2,3,23,24}

Author Affiliations:

\textsuperscript{1}Children’s Hospital Colorado and University of Colorado School of Medicine Departments of Pediatrics, Pharmacology\textsuperscript{3}, Neurology\textsuperscript{23} and Otolaryngology\textsuperscript{24}, Aurora, CO, USA

\textsuperscript{3}Cleveland Clinic, Neurological Institute and Epilepsy Center\textsuperscript{4}, Cleveland, OH, USA

\textsuperscript{5}Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Boston Children’s Hospital, Boston, MA USA

\textsuperscript{6}Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia

\textsuperscript{7}School of Physiotherapy and Exercise Science, Curtin University, Perth, Western Australia, Australia

\textsuperscript{8}Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA USA and Departments of Neurology and Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA USA

\textsuperscript{9}M.I.N.D. Institute, Department of Neurology, University of California Davis Health System, Sacramento, CA, USA and Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA

\textsuperscript{10}CDKL5 UK, Somerset, UK

\textsuperscript{11}Department of Computer Science, University of Western Ontario, and Pulse Infoframe, London, Ontario, Canada.

\textsuperscript{12}CDKL5 Research Collaborative, Dexter, MI, USA

\textsuperscript{13}UCL Great Ormond Street Institute of Child Health & NIHR GOSH BRC, London, UK
14 University of Edinburgh and Royal Hospital for Sick Children, Edinburgh, UK

15 DRK Westend Clinic Berlin, Berlin, Germany

16 Neurology, Division of Pediatric Neurology, Epilepsy Section, Washington University School of Medicine, St. Louis Children's Hospital, St Louis, MO, USA

17 International Foundation for CDKL5 Research, Wadsworth, OH, USA

18 University of Bristol, UK

19 Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development NORD, Basel, Switzerland

20 Department of Neurology, New York University, New York, NY, USA.

21 Vanderbilt Kennedy Center, Vanderbilt University Medical Center, TN, USA

22 University of Alabama at Birmingham, Pediatrics, Neurology, Neurobiology, Genetics, and Psychology, Birmingham, AL, USA

*Corresponding author. Email: tim.benke@ucdenver.edu
Abstract

Background: Pathological mutations in cyclin-dependent kinase-like 5 cause CDKL5 deficiency disorder (CDD), a genetic syndrome associated with severe epilepsy, cognitive, motor, visual and autonomic disturbances. CDD is a relatively common genetic cause of early-life epilepsy. A specific severity assessment is lacking, required to monitor clinical course, define the natural history and for clinical trial readiness.

Methods: A severity assessment was developed based on clinical and research experience from the International Foundation for CDKL5 Research Centers of Excellence consortium and the NIH Rett and Rett-related disorders Natural History Study consortium. An initial draft severity assessment was presented and reviewed at the annual CDKL5 Forum meeting (Boston, 2017). Subsequently it was iterated through four cycles of a modified Delphi process by a group of clinicians, researchers, industry, patient advisory groups and parents familiar with this disorder until consensus was achieved. The revised version of the severity assessment was presented for review, comment and piloting to families at the International Foundation for CDKL5 Research sponsored family meeting (Colorado, 2018). Final revisions were based on this additional input.

Results: The final severity assessment comprised 51 items that comprehensively describe domains of epilepsy, motor, cognition, behavior, vision, speech and autonomic function. Parental ratings of therapy effectiveness, child and family functioning are also included.

Conclusions: A severity assessment was rapidly developed with input from multiple stake-holders. Refinement through ongoing validation is required for future clinical trials. The consensus methods employed for the development of the severity assessment may be applicable to similar rare disorders.

Key words: CDKL5; rare disorder; severity assessment; epilepsy; cortical visual impairment; intellectual disability.
Introduction

Pathological mutations in cyclin-dependent kinase-like 5 (CDKL5)\cite{1-5} result in CDKL5 Deficiency Disorder Disorder (CDD, OMIM 300203, 300672, also referred to as CDKL5 Disorder, CDKL5 Syndrome and CDKL5). Previously considered a “Rett variant”, this unique disorder \cite{6, 7}, has overlapping features with many of the developmental encephalopathies, disorders defined by genetic or presumed genetic etiology, severe seizures and intellectual/cognitive disability\cite{8}. Incidence varies from ~1:40,000 -60,000\cite{9-11}; approximately one-half to one-third as common as Dravet syndrome (1:20,000-50,000)\cite{12, 13} or Rett syndrome (1:10,000 female births)\cite{14}. Thus, CDD is a diagnostic consideration in young children with severe, early-onset epilepsy.

CDD is associated with high rates of severe epilepsy as well as cognitive, motor, visual and autonomic disturbances \cite{4, 15-22}. Although surveys have reported the characteristics and frequency of CDD features\cite{6}, no clinical severity assessment has integrated CDD’s clinical manifestations. Assessments for Rett Syndrome\cite{23-26}, FOXG1\cite{27}, tuberous sclerosis\cite{28}, and other developmental epileptic encephalopathies\cite{29, 30} incorporate many CDD features, but none provide a focused nor comprehensive assessment of CDD patients. A specific severity CDD assessment targeting all clinical features is lacking and needed for clinicians to evaluate care, define natural history, inform specialist and therapeutic referrals, and with appropriate validation, to assess the outcomes of interventions in clinical trials. Given the recent initiation of human therapeutic trials (CBD\cite{31}, Ataluren ClinicalTrials.gov: NCT02758626, ganaxalone ClinicalTrials.gov: NCT03572933, TAK-935 ClinicalTrials.gov: NCT03694275) and the reversibility of symptoms in CDD animal models\cite{32}, a validated assessment is urgently needed for CDD clinical trials.

We established a uniform clinical approach to patients as part of the International Foundation for CDKL5 research (IFCR) Centers of Excellence (COE) at three sites (Children’s Hospital Colorado/University of Colorado School of Medicine, Boston Children’s Hospital and Cleveland Clinic) and sites associated with
the NIH-funded Rett and Rett-related disorders Natural History Study (NHS) (U54 HD061222; ClinicalTrials.gov: NCT00299312/NCT02738281). Each site collects clinical or research data on CDD patients. Application of scales and assessments developed for Rett syndrome were not adequate to capture unique features of CDD. The CDD Severity Assessment (CDD-SA) intends to capture unique features of CDD, such as epilepsy severity, cognitive, motor and visual impairment and specific aspects of movement disorder. This assessment needs to be comprehensive but efficient to administer. It must capture the distribution of abilities of CDD patients without saturating. Given the multiple stakeholders with overlapping goals for this type of assessment, we supplemented our clinical research infrastructure by recruiting into our group an international and multi-disciplinary panel of clinicians, researchers and industry professionals outside of the COE and NHS along with parents of patients directly involved in CDD patient advocacy groups. This collaboration provided input to develop and refine the CDD-SA as described here.

Methods

Clinically obtained or research-subject data available under IRB approvals (COMIRB 13-2020, 15-2332, Cleveland Clinic IRB 14-478, need Boston COE IRB P00016602 and UAB NHS parent IRB F150518001) of 111 unique patients with CDD were reviewed. Based on these data, review of available scales and literature noted above, an initial CDD-SA was developed by the principal investigator (PI: TAB) and presented at the annual CDKL5 Forum meeting (Boston, November 2017). This was followed by an open forum allowing input from stakeholders for feedback and queries. Revisions were made based on this input. We questioned whether the CDD-SA should be for clinical or research purposes, the potential domains to assess, the optimal type(s) of response scale to use, and the time-frame of evaluation that is assessed (e.g., birth to present, prior 6 months to present, last month to present and last week to present). Domains considered to be relevant included: overall severity of disorder, epilepsy, cognition, motor
function, vision, autonomic disturbances and movement disorders. Response scale that were considered included: 5-point scales (evaluating frequency or severity of a feature), Likert scales (evaluating the appropriateness of a statement) and global impressions of severity or change (caregiver- and clinician global impression scales). We agreed that a clinical component provided by an examination was needed to complement and inform caregiver reported observations, leading to parent and clinician sections of the CDD-SA.

The CDD-SA was then iteratively evaluated through four cycles of anonymous modified Delphi[33] comment and consensus by an international panel of clinicians, researchers, industry, patient advisory groups and parents familiar with CDD (Figure 1). The group grew in numbers from those initially present at the Boston LouLou Foundation CDKL5 Forum to the full CDD-SA advisory group (SAAG, Table 1). Each CDD-SA version was emailed to the group and returned to the PI with comments and suggested changes. The number of questions in each domain, the specific items in each domain and the wording of items were debated and modified to accurately reflect experiences of each group of contributors. The number of items began at 24 and converged by the 3rd round to approximately 50 items, similar to the final. The feasibility of applying the CDD-SA in a clinical setting led to a reduction of items in each domain. The PI reviewed all comments, developed an independently ascertained best consensus from suggested changes, revised the CDD-SA and returned this to the review group with prior anonymous comments to provide historical background from the previous CDD-SA version. This allowed the group to understand the rationale for emerging consensus and provide commentary as to whether the emerging consensus was tracking with the intended changes to the CDD-SA. While this was not a survey-based approach like a traditional Delphi process the overall method of eliciting feedback and creating consensus was similar. The number of participants remained consistent throughout the review period, with no drop outs, providing a representative stakeholder input. The penultimate CDD-SA version was presented by the PI at the IFCR annual meeting to parents of over 100 CDD patients (Denver, June 2018) for review, comment
and trial. All families present were provided access to the CDD-SA and comments were solicited and received for a duration of four weeks after the conference. Two families (whose children were not managed by the PI) agreed to trial the CDD-SA at the meeting; the time to administer the CDD-SA was measured and collected. The final revision of the CDD-SA was based on this additional input to result in the current CDD-SA (Figure 2). There was full consensus by SAAG members on the final CDD-SA.

Results

After multiple revisions by the SAAG, the domains selected were epilepsy, cognition and motor, vision and autonomic function. Movement disorders were included within the motor domain. Clinical examination components were separated from the parent-report section within the cognition, motor, vision, and autonomic domains. This allowed a combination of parent or caregiver-report and a clinician completed portion based on physical exam findings. Parental components would be completed prior to the clinical examination; the time to complete this component has not yet been captured. In a pilot clinical examination, the parent portion was reviewed and the clinical portion was completed in 30 minutes by each of the two volunteer families.

Use of a global impression of severity[24] was rejected by the SAAG because these impression scales may rate self (caregiver)-described and patient-specific features that limit comparisons between patients. Thus the clinical value of a global impression of severity may not translate to research settings and could be a limitation in that context. The 5-point scale (0=normal, 5=most severe), similar to that used in the Rett syndrome Motor-Behavioral Assessment (MBA) [25] was selected, with higher scores more severe. Likert scales were added, as a compromise to deletion of the global impressions scale, for ratings of overall child improvement and parent/caregiver resilience and adaptability (-5=worse, 0 = no change, 5=best possible) and evaluation of therapies (-5=worse, 0 = no change, 5=best possible).
The SAAG determined that the CDD-SA evaluation time-frame should reflect developmental and longitudinal changes[20]. Use of the birth-to-present questions were limited since they could reflect ceiling effects or static assessments that would be insensitive to change. Month-to-present time-frames were considered most likely to reflect accurate changes, though week-to-present time-frames could be substituted if a clinical trial required frequent assessments. Since clinical assessments not part of a clinical trial may occur at 6-monthly intervals, 6-month to present time-frames were also included.

The wording of the items was simplified during the iterations substantially, especially in the epilepsy domain given the complexities of classifying seizures. CDD is associated with multiple seizure types, including prolonged and atypical aura, epileptic spasms, tonic, tonic-clonic, myoclonic and atypical absence [18, 19, 22, 34-36]. Further, a single seizure may involve multiple types that evolve, while other seizures can be challenging to characterize even by experts using video EEG [37]. This feature of epilepsy associated with CDD makes traditional seizure counting difficult for parents and caregivers [38, 39]. Rather, estimates of frequency and impact on function were agreed upon instead. While this approach substitutes one subjective assessment for another, it becomes more patient-centered.

The clinical portion was based on features typically evaluated during an exam by a pediatric neurologist. However, certain CDD-SA components would likely add time to the routine visit, especially if that clinical visit includes a discussion of clinical decision making. Regardless of the country and practice considerations, the CDD-SA had to provide relevant data that could be assimilated and utilized at a clinical visit. The final domains and details of the exam were considered recommendations: clinicians would tailor their approach such that not every item within their usual assessment would necessarily be included for all visits or all patients, although the items seek to limit clinician-to-clinician variability. It can be challenging to assess the breadth of features and the functional impact of movement disorders within a clinical visit. Also, any clinical examination is a snap-shot in time, and may not assess some areas captured for which extended observation by a parent or caregiver may be more informative. There are similar
challenges when assessing cognition and vision in CDD patients who are often non-verbal and have some
degree of visual impairment. Cognition assessment is limited by both exam time and CDD features to
assessing choice and visual attention in the CDD-SA.

In summary (Table 2 and Figure 2), the final CDD-SA comprised 4 domains: 1) Epilepsy, 2) Motor,
3) Cognition, Behavior and Vision and 4) Autonomic, that are nearly equally weighted with similar
maximum scores (69, 65, 65 and 44, respectively) on items that mostly were scored on a 0 to 5 range.
Impressions of overall improvement, parent/caregiver resiliency and therapy utility were each given a -5
to 5 Likert scale. An optional part of the CDD-SA was medical decision making. While no points were
assigned to each intervention, the goal was to provide a formulaic framework to track the impact of these
when the CDD-SA is used in a primarily clinical setting. Secondary scoring of data to reflect impact could
be developed based on features such as patient discomfort and invasiveness, financial impact, impact to
parent/caregivers, etc.

Discussion and Conclusions

Using a modified Delphi process, we developed a new clinically relevant and easily administered
severity assessment (SA) for CDD (CDD-SA). With on-going natural history studies such as the NIH-funded
NHS and current and planned drug trials specifically for patients with CDD, our CDD-SA offers the ability
capture aspects of this disorder that may change with time or in response to interventions. In the first
instance, we have provided some evidence for its content validity, basing the CDD-SA on available
literature, the clinical and research experience of an international panel of experts and the lived
experience of our parent participants. We achieved a consensus across a broad spectrum of international
clinicians from multiple specialties and subspecialties, parents, lay organizations and industry
professionals to develop this CDD-SA.
A limitation of the process was the lack of a framework with an objective ‘gold-standard’ to validate our CDD-SA. Further, both the stakeholders and the PI could not reliably determine the relative value of specific recommendations, nor the validity of the scale to measure the feature of interest. Bias by the PI in adjudicating disagreements and alternative views could be an inherent limit of this process but was countered by extensive expertise of the investigators and the lived experiences of families in the consultation process. The SAAG input helped ensure the comprehensive and disease appropriate nature of the CDD-SA and it is unlikely that the primary domains will need major alterations in the future. The SAAG-approved SA is being applied in CDD Centers of Excellence and can be applied in other clinical and research settings. This will provide the basis for future validation that will include some refinement of necessary items and language. In addition, qualitative data is needed to validate parental interpretations of questions and refine future versions in order to determine the sensitivity of the CDD-SA. A quantitative dataset with a large sample size will be necessary to determine change with interventions, evaluate interrater reliability, factor analyses, stability and responsiveness over time.

We propose that our clinical assessment will have immediate utility with clinicians who see children with CDD. The CDD-SA is freely available for general use. This methodology could be applied to the development of clinical assessments for other rare genetic disorders and the framework could potentially serve as an early foundation to other constituent organizations. Key aspects that allowed this to happen included an initial framework (COE and NHS) that standardized the identification of clinical features relevant to CDD. Next, those that were outside of the COE and NHS were included in the process. The support of patient advocacy groups and associated parents/caregivers provided mission-critical context. Finally, a willingness to collaborate by the SAAG despite many other commitments and time constraints allowed the process to move forward.

Acknowledgements:
We sincerely thank all of the patients and families that have participated in this research.

Scott Demarest: NIH/NINDS NSADA K12 (1K12NS089417-01), Children’s Hospital Colorado Research Institute and the International Foundation for CDKL5 Research

Elia M. Pestana Knight: nothing to declare.

Jenny Downs: International Foundation for CDKL5 Research, NHMRC #1103745

Heather Olson: International Foundation for CDKL5 Research, NIH/NINDS K23 NS107646-01

Eric D. Marsh: NIH U54 HD061222

Walter E. Kaufmann: International Foundation for CDKL5 Research

Carol-Anne Partridge: nothing to declare

Helen Leonard: NHMRC Senior Research Fellowship #1103741, International Foundation for CDKL5 Research

Femida Gwadry-Sridhar: nothing to declare

Katheryn Elibri Frame: nothing to declare

J. Helen Cross: nothing to declare

Richard F. M. Chin: nothing to declare

Sumit Parikh: International Foundation for CDKL5 Research

Axel Panzer: nothing to declare

Judith Weisenberg: International Foundation for CDKL5 Research

Karen Utley: nothing to declare

Amanda Jaksha: nothing to declare

Sam Amin: nothing to declare.

Omar Khwaja: nothing to declare

Orin Devinsky: nothing to declare

Jeffery L. Neul: NIH U54 HD061222

Alan K. Percy: NIH U54 HD061222; Rett Syndrome Research Trust
Declaration of interest:

Scott Demarest: Consulting for Upsher-Smith and BioMarin. All remuneration has been made to his department.

Elia M. Pestana Knight: None

Jenny Downs: Consultancy for Avexis and Marinus.

Heather Olson: None

Eric D. Marsh: Funding from the NIH, Rettsyndrome.org, and Rett Syndrome Research Trust, Site PI on studies from GW pharma, Zogenix Pharma, Marinus pharma, consultant to Stoke therapeutics.

Walter E. Kaufmann: None

Carol-Anne Partridge: None

Helen Leonard: None

Femida Gwadry-Sridhar: None

Katheryn Elibri Frame: None

J. Helen Cross: J Helen Cross has participated as a clinical investigator for Zogenix, GW Pharma, Marinius Pharmaceuticals and Vitaflo. She has been a member of advisory boards and speaker for Eisai, GW Pharma, Nutricia and Zogenix. All remuneration has been made to her department.

Richard F. M. Chin: None

Sumit Parikh: None

Axel Panzer: None

Judith Weisenberg: None

Karen Utley: None

Amanda Jaksha: None
Sam Amin: None.

Omar Khwaja: None

Orin Devinsky: Consultancy/advisory: Privateer Holdings/Tilray, Egg Rock/Papa & Barkley, Receptor Life Sciences, Empatica, Tevard, Engage, Rettco, Pairnomix/Q-state, Zogenix and GW Pharmaceuticals.

Jeffery L. Neul: Funding from the NIH, Consultancy with Acadia, AveXis, Biohaven, GW Pharmaceuticals, Neuren, Newron, Takeda, Teva

Alan K. Percy: Consultancy for Anavex, AveXIs, and GW Pharmaceuticals; Clinical Trial with Newron Pharmaceuticals

Tim A. Benke: Consultancy for AveXis, Ovid, Takeda and Marinus. All remuneration has been made to his department.
Table 1: CDD Severity Assessment Advisory Group (SAAG). Affiliations for non-authors noted.

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sam Amin</td>
<td>Helen Leonard</td>
</tr>
<tr>
<td>Richard Chin</td>
<td>Eric Marsh</td>
</tr>
<tr>
<td>J Helen Cross</td>
<td>Lorraine Masuoka (Marinus)</td>
</tr>
<tr>
<td>Scott Demarest</td>
<td>Jeff Neul</td>
</tr>
<tr>
<td>Orrin Devinsky</td>
<td>Heather Olson</td>
</tr>
<tr>
<td>Jenny Downs</td>
<td>Axel Panzer</td>
</tr>
<tr>
<td>Katheryn Frame</td>
<td>Sumit Parikh</td>
</tr>
<tr>
<td>Jayne Gershkowitz (Amicus)</td>
<td>Carol-Anne Partridge</td>
</tr>
<tr>
<td>Femida Gwadry-Sridhar</td>
<td>Alan Percy</td>
</tr>
<tr>
<td>Joe Horrigan (Amo)</td>
<td>Elia M. Pestana-Knight</td>
</tr>
<tr>
<td>Amanda Jaksha</td>
<td>Sunny Phil (University of Birmingham, UK)</td>
</tr>
<tr>
<td>Walter Kaufmann</td>
<td>Robin Ryther (Washington University, USA)</td>
</tr>
<tr>
<td>Michael Johnson (Imperial College, UK)</td>
<td>Meghan Thorne-Miller (Roche)</td>
</tr>
<tr>
<td>Omar Khwaja</td>
<td>Karen Utley</td>
</tr>
<tr>
<td>Denise Lasbury (CDKL5-UK)</td>
<td>Judy Weisenberg</td>
</tr>
<tr>
<td>Dan Lavery (LouLou Foundation)</td>
<td>Ashley Winslow (LouLou Foundation)</td>
</tr>
</tbody>
</table>

Table 2. Composition of the CDD-SA by domain and source of data

<table>
<thead>
<tr>
<th>Domain</th>
<th>By Caregiver</th>
<th># questions</th>
<th>By Clinicians</th>
<th># questions</th>
<th>Total # questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Epilepsy</td>
<td>Yes</td>
<td>15</td>
<td>No</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>2. Motor</td>
<td>No</td>
<td>0</td>
<td>Yes</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>3. Cognition and Vision</td>
<td>Yes</td>
<td>1</td>
<td>Yes</td>
<td>12</td>
<td>13</td>
</tr>
<tr>
<td>4. Autonomic</td>
<td>Yes</td>
<td>9</td>
<td>Yes</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>5. Overall</td>
<td>Yes</td>
<td>2</td>
<td>No</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>6. Therapies</td>
<td>Yes</td>
<td>1</td>
<td>No</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>7. Scale Scoring</td>
<td>No</td>
<td>-</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Visit notes</td>
<td>No</td>
<td>-</td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 1: Modified Delphi process for CDD-SA development.

Figure 2: CDD-SA. The Final CDD-SA with brief instructions on completion.
References


